Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Here is the latest stock price and chart of Novartis. For more details, see the Novartis company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Live BSE Quotes | Apr 20, 2018 (Close) | ||
---|---|---|---|
Price (Rs)639.40 | Open (Rs) 626.10 | High (Rs) 645.00 | Low (Rs) 626.10 |
% Change1.10 | Volume 8,984 | Value (Rs) 5,742,777 | 52-Week H/L 730.00 / 579.00 |
Live NSE Quotes |
---|
Not listed |
Valuation | |||
---|---|---|---|
EPS (Rs)* 1.71 | P/E Ratio (x) 374.86 | Market Cap (Rs m) 214,493.12 | P/BV (x) 18.46 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
S&P BSE SENSEX ![]() |
||||||
PERIOD |
NOVARTIS last traded price was up 1.1% to Rs 639.4 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.0%. And the benchmark S&P BSE SENSEX was at 34,415.6 (down 0.0%).
Over the last 30 days, the NOVARTIS share price is up 6.1%. And over the last one year, NOVARTIS share price is down 11.6%.
| |
After opening their day on a negative note, Indian share markets witnessed choppy trades and ended their session on a flat note.
US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Price erosion in generic US drugs continues but seems to be bottoming out.
Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
More Views on NewsIt is basically a supply problem with not enough currency going around in the financial system.
I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.
Rajeev Thakkar tells us how teachings from Vipassana can help you became a better investor.
How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.
PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan
More
| |